High bone marrow ID2 expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia
PDF | HTML | How to cite
Metrics: PDF 1175 views | HTML 2016 views | ?
Jing-Dong Zhou1,3,*, Ji-Chun Ma2,3,*, Ting-Juan Zhang1,3,*, Xi-Xi Li1,3, Wei Zhang1,3, De-Hong Wu4, Xiang-Mei Wen2,3, Zi-Jun Xu2,3, Jiang Lin2,3 and Jun Qian1,3
1Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China
2Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China
3The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People’s Republic of China
4Department of Hematology, The Third People’s Hospital of KunShan City, Suzhou, Jiangsu, People’s Republic of China
*These authors have contributed equally to this work
Jun Qian, email: [email protected]
Jiang Lin, email: [email protected]
Keywords: ID2, expression, prognosis, TCGA, AML
Received: June 22, 2017 Accepted: August 09, 2017 Published: September 01, 2017
Dysregulation of ID proteins is a frequent event in various human cancers and has a direct role in cancer initiation, maintenance, progression and drug resistance. Our previous study has revealed ID1 expression and its prognostic value in acute myeloid leukemia (AML). Herein, we further reported ID2 expression and its clinical significance in AML. Real-time quantitative PCR was performed to detect ID2 transcript level in bone marrow mononuclear cells of 145 de novo AML patients. ID2 expression was significantly up-regulated in AML patients compared with controls. ID2 overexpression occurred with the highest frequency in poor karyotype (10/17, 59%), lower in intermediate karyotype (35/83, 42%), and the lowest in favorable karyotype (7/40, 18%). Moreover, high ID2 expression correlated with lower complete remission (CR) rate, shorter overall survival, and acted as an independent prognostic biomarker in whole-cohort AML and non-M3-AML patients. Importantly, the prognostic value of ID2 expression in AML was validated by The Cancer Genome Atlas (TCGA) data. In the follow-up of patients, ID2 expression at CR phase was decreased than at the time of diagnosis, and was increased again at the time of relapse. These findings demonstrated that bone marrow ID2 overexpression was a frequent event in AML patients, and predicts poor chemotherapy response and prognosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.